logo
Медицинский вестник
Северного Кавказа
Научно-практический журнал
Зарегистрирован в Федеральной службе
по надзору за соблюдением законодательства
в сфере массовых коммуникаций
и охране культурного наследия
ПИ №ФС77-26521 от 7 декабря 2006 года
ISSN 2073-8137
rus
русский
eng
english

Поиск по сайту




Адрес редакции
355017, Ставрополь, улица Мира, 310.

Телефоны
(8652) 35-25-11, 35-32-29.

E-mail
medvestnik@stgmu.ru

Рейтинг@Mail.ru

Перспективы лечения неалкогольной жировой болезни печени

[Обзоры]
Корой Павел Владимирович; Сляднев Сергей Александрович; Ягода Александр Валентинович;

В обзоре представлен анализ данных литературы по проблеме терапии неалкогольной жировой болезни печени. Рассмотрено позитивное влияние модификации образа жизни, бариатрической хирургии, коррекции нарушений углеводного, липидного обмена, применения витаминов, антиоксидантов и гепатопротекторов на клинические, биохимические и гистологические проявления заболевания.

Скачать

Список литературы:
1. Гейвандова, Н. И. Влияние инсулиновых сенситайзеров на некоторые показатели воспаления при неалкогольной жировой болезни печени / Н. И. Гейвандова, Н. Г. Белова, О. В. Фалеева, Г. А. Александрович // Медицинский вестник Северного Кавказа. – 2011. – № 3. – С. 106–107.
2. Драпкина, О. М. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903) / О. М. Драпкина, В. Т. Ивашкин // Рос. журн. гастроэнтерол., гепатол., колопроктол. – 2014. – Т. 24, № 4. – С. 32–38.
3. Маев, И. В. Применение фосфоглива в лечении больных неалкогольным стеатогепатитом / И. В. Маев, Е. С. Вьючнова, С. М. Бабина // Российские медицинские вести. – 2009. – Т. XIV, № 4. – С. 20–28.
4. Мойсеенко, В. А. Возможности применения препарата «Фосфоглив» в лечении стеатогепатита с сопутствующим хроническим колитом / В. А. Мойсеенко, Э. Г. Манжалий // Сучасна Гастроентерологія. – 2014. – № 2. – С. 107–115.
5. Aithal, G. P. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis / G. P. Aithal, J. A. Thomas, P. V. Kaye [et al.] // Gastroenterology. – 2008. – Vol. 135. – P. 1176–1184.
6. Akyuz, F. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease / F. Akyuz, K. Demir, S. Ozdil [et al.] // Dig. Dis. Sci. – 2007. – Vol. 52, № 9. – P. 2359–2367.
7. Athyros, V. G. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis / V. G. Athyros, K. Tziomalos, T. D. Gossios [et al.] // Lancet. – 2010. – Vol. 376. – P. 1916–1922.
8. Bjelakovic, G. Meta-analysis: antioxidant supplements for liver disease – the Cochrane Hepato-Biliary Group / G. Bjelakovic, L. L. Gluud, D. Nikolova [et al.] // Aliment. Pharmacol. Ther. – 2010. – Vol. 32. – P. 356–367.
9. Bloomgarden, Z. T. Second World Congress on the Insulin Resistance Syndrome. Insulin resistance syndrome and nonalcoholic fatty liver disease / Z. T. Bloomgarden // Diabetes Care. – 2005. – Vol. 28, № 6. – Р. 1518–1523.
10. Brea, A. Non-alcoholic fatty liver disease and cardiovascular risk / A. Brea, J. Puzo // Int. J. Cardiol. – 2013. – Vol. 167, № 4. – P. 1109–1117.
11. Centis, E. The effect of lifestyle changes in non-alcoholic fatty liver disease / E. Centis, R. Marzocchi, S. Di Domizio [et al.] // Dig. Dis. – 2010. – Vol. 28, № 1. – P. 267–273.
12. Chalasani, N. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Gastroenterology. – 2012. – Vol. 142, № 7. – P. 1592–609.
13. Chen, H. P. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies / H. P. Chen, J. J. Shieh, C. C. Chang [et al.] // Gut. – 2013. – Vol. 62, № 4. – P. 606–615.
14. Dietrich, M. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? / M. Dietrich, P. F. Jacques, M. J. Pencina [et al.] // Atherosclerosis. – 2009. – Vol. 205. – P. 549–553.
15. Du, J. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis / J. Du, Y. Y. Ma, C. H. Yu, Y. M. Li // World. J. Gastroenterol. – 2014. – Vol. 20, № 2. – P. 569–577.
16. Eckard, C. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial / C. Eckard, R. Соle, J. Lockwood [et al.] // Therap. Adv. Gastroenterol. – 2013. – Vol. 6, № 4. – P. 249–259.
17. Ekstedt, M. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study / M. Ekstedt, L. E. Franzen, U. L. Mathiesen [et al.] // J. Hepatol. – 2007. – Vol. 47. – P. 135–141.
18. El-Lakkany, N. The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental schistosomiasis mansoni / N. El-Lakkany, S. S. El-Din, F. Ebeid // Exp. Parasitol. – 2011. – Vol. 129, № 2. – P. 152–157.
19. Foster, T. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial / T. Foster, M. J. Budoff, S. Saab [et al.] // Am. J. Gastroenterol. – 2011. – Vol. 106. – P. 71–77.
20. Geyvandova, N. I. Possibilities of original «Bicyclol» medicine in therapy of chronic hepatitis C / N. I. Geyvandova, D. A. Lioznov, V. G. Morozov et al. // Medical news of North Caucasus. – 2015. – Vоl. 10, № 2. – P. 173–177.
21. Harrison, S. A. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial / S. A. Harrison, E. M. Brunt, W. J. Fecht, B. A. Neuschwander-Tetri // Hepatology. – 2009. – Vol. 49. – P. 80–86.
22. Hoofnagle, J. H. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis / J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner [et al.] // Aliment. Pharmacol. Ther. – 2013. – Vol. 38, № 2. – P. 134–143.
23. Hung, C. H. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection / C. H. Hung, J. H. Wang, T. H. Hu [et al.] // World. J. Gastroenterol. – 2010. – Vol. 16, № 18. – P. 2265–2271.
24. Hyogo, H. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia / H. Hyogo, S. Tazuma, K. Arihiro [et al.] // Metabolism. – 2008. – Vol. 57, № 12. – P. 1711–1718.
25. Iwasaki, T. Sitagliptin as a novel treatment agent for nonalcoholic fatty liver disease patients with type 2 diabetes mellitus / T. Iwasaki, M. Yoneda, M. Inamori [et al.] // Hepatogastroenterology. – 2011. – Vol. 58. – P. 2103–2105.
26. Klein, E. A. Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT) / E. A. Klein, I. M. Thompson, C. M. Tangen [et al.] // JAMA. – 2011. – Vol. 306. – P. 1549–1556.
27. Lavine, J. E. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial / J. E. Lavine, J. B. Schwimmer, M. L. Van Natta [et al.] // JAMA. – 2011. – Vol. 305, № 16. – P. 1659–1668.
28. Lazo, M. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes / M. Lazo, S. F. Solga, A. Horska [et al.] // Diabetes. Care. – 2010. – Vol. 33. – P. 2156–2163.
29. Leushner, U. High-dose Ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial / U. Leushner, B. Li denthal, G. Herrman [et al.] // Hepatology. – 2010. – Vol. 52. – P. 472–479.
30. Lincoff, A. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials / A. Lincoff, K. Wolski, S. Nicholls, S. Nissen // JAMA. – 2007. – Vol. 298. – P. 1180-1188.
31. Loomba, R. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis / R. Loomba, G. Lutchman, D. E. Kleiner [et al.] // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 172–182.
32. Magkos, F. Exercise and fat accumulation in the human liver / F. Magkos // Curr. Opin. Lipidol. – 2010. – Vol. 21. – P. 507–517.
33. Marra, F. Pathophysiology of NASH: perspectives for a targeted treatment / F. Marra, S. Lotersztajn // Curr. Pharm. Des. – 2013. – Vol. 19, № 29. – P. 5250-5269.
34. Mathurin, P. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease / P. Mathurin, A. Hollebecque, L. Arnalsteen [et al.] // Gastroenterology. – 2009. – Vol. 137. – P. 532–540.
35. Menegazzi, M. Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice / M. Menegazzi, R. Di Paola, E. Mazzon [et al.] // Pharmacol. Res. – 2008. – Vol. 58, № 1. – P. 22–31.
36. Musso, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease / G. Musso, R. Gambino, M. Cassader, G. Pagano // Hepatology. – 2010. – Vol. 52. – P. 79–104.
37. Omer, Z. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease / Z. Omer, S. Cetinkalp, M. Akyildiz [et al.] // Eur. J. Gastroenterol. Hepatology. – 2010. – Vol. 22. – P. 18–23.
38. Park, H. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease / H. Park, T. Shima, K. Yamaguchi [et al.] // J. Gastroenterol. – 2011. – Vol. 46. – P. 101–107.
39. Parker, H. M. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis / H. M. Parker, N. A. Johnson, C. A. Burdon [et al.] // J. Hepatol. – 2012. – Vol. 56. – P. 944–951.
40. Petta, S. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients / S. Petta, G. Marchesini, L. Caracausi [et al.] // J. Hepatol. – 2013. – Vol. 59, № 6. – P. 1169–1176.
41. Promrat, K. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis / K. Promrat, D. E. Kleiner, H. M. Niemeier [et al.] // Hepatology. – 2010. – Vol. 51. – P. 121–129.
42. Rakoski, M. O. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis / M. O. Rakoski, A. G. Singal, M. A. Rogers, H. Conjeevaram // Aliment. Pharmacol. Ther. – 2010. – Vol. 32. – P. 1211–1221.
43. Ratziu, V. A randomized controlled trial of hig-dose ursogeoxycholic acid for nonalcoholic steatohepatitis / V. Ratziu, V. de Ledinghen, F. Oberti [et al.] // J. Hepatol. – 2011. – Vol. 54. – P. 1011–1019.
44. Ratziu, V. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT-2) extension trial / V. Ratziu, F. Charlotte, C. Bernhardt [et al.] // Hepatology. – 2010. – Vol. 51. – P. 445–453.
45. Samson, S. L. Potential of incretin-based therapies for non-alcoholic fatty liver disease / S. L. Samson, M. Bajaj // J. Diabetes. Complications. – 2013. – Vol. 27, № 4. – P. 401–406.
46. Sanyal, A. J. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis / A. J. Sanyal, N. Chalasani, K. V. Kowdley [et al.] // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1675–1685.
47. Sato, K. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials / K. Sato, M. Gosho, T. Yamamoto [et al.] // Nutrition. – 2015. – Vol. 31, № 7–8. – P. 923–930.
48. Shargorodsky, M. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? / M. Shargorodsky, E. Omelchenko, Z. Matas [et al.] // Cardiovasc. Diabetol. – 2012. – Vol. 7, № 11. – P. 61–64.
49. Simopoulos, A. P. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease / A. P. Simopoulos // Nutrients. – 2013. – Vol. 5, № 8. – P. 2901–2923.
50. Su, H. L. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease / H. L. Su, Y. X. Zhu, Z. J. Gao [et al.] // Chin. J. Hepatol. – 2011. – Vol. 19, № 7. – P. 552–553.
51. Targher, G. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease / G. Targher, C. P. Day, E. Bonora // N. Engl. J. Med. – 2010. – Vol. 363. – P. 1341–1350.
52. van der Heijden, G. J. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents / G. J. van der Heijden, Z. J. Wang, Z. D. Chu [et al.] // Obesity. – 2010. – Vol. 18. – P. 384–390.
53. Vernon, G. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults / G. Vernon, A. Baranova, Z. M. Younossi // Aliment. Pharmacol. Ther. – 2011. – Vol. 34. – P. 274–285.
54. Viljanen, A. P. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance / A. P. Viljanen, P. Iozzo, R. Borra [et al.] // J. Clin. Endocrinol. Metab. – 2009. – Vol. 94. – P. 50–55.
55. Wong, V. W. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study / V. W. Wong, G. L. Won, A. M. Chim [et al.] // Ann. Hepatol. – 2013. – Vol. 12. – P. 256–262.
56. Yoneda, M. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study / M. Yoneda, K. Fujita, Y. Nozaki [et al.] // Hepatol. Res. – 2010. – Vol. 40. – P. 566–573.
57. Zein, C. O. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism / C. O. Zein, R. Lopez, X. Fu [et al.] // Hepatology. – 2012. – Vol. 56, № 4. – P. 1291–1299.
58. Zein, C. O. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial / C. O. Zein, L. M. Yerian, P. Gogate [et al.] // Hepatology. – 2011. – Vol. 54, № 5. – P. 1610–1619.
59. Zeng, T. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies / T. Zeng, C. L. Zhang, X. L. Zhao, K. Q. Xie // Еur. J. Gastroenterol. Hepatol. – 2014. – Vol. 26, № 6. – P. 646–653.
60. Zhou, M. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin / M. Zhou, A. Xu, K. S. Lam [et al.] // J. Hepatol. – 2010. – Vol. 53, № 6. – P. 1108–1116.

Ключевые слова: неалкогольная жировая болезнь печени, неалкогольный стеатогепатит, терапия


Учредители:
Ставропольская государственная медицинская академия
Государственный научно-исследовательский институт курортологии
Пятигорская государственная фармацевтическая академия